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BACKGROUND: Despite a modest association between tobacco smoking and breast cancer risk reported by recent epidemiological
studies, it is still equivocal whether smoking is causally related to breast cancer risk.
METHODS: We applied Mendelian randomisation (MR) to evaluate a potential causal effect of cigarette smoking on breast cancer
risk. Both individual-level data as well as summary statistics for 164 single-nucleotide polymorphisms (SNPs) reported in genome-
wide association studies of lifetime smoking index (LSI) or cigarette per day (CPD) were used to obtain MR effect estimates. Data
from 108,420 invasive breast cancer cases and 87,681 controls were used for the LSI analysis and for the CPD analysis conducted
among ever-smokers from 26,147 cancer cases and 26,072 controls. Sensitivity analyses were conducted to address pleiotropy.
RESULTS: Genetically predicted LSI was associated with increased breast cancer risk (OR 1.18 per SD, 95% CI: 1.07–1.30, P= 0.11 ×
10–2), but there was no evidence of association for genetically predicted CPD (OR 1.02, 95% CI: 0.78–1.19, P= 0.85). The sensitivity
analyses yielded similar results and showed no strong evidence of pleiotropic effect.
CONCLUSION: Our MR study provides supportive evidence for a potential causal association with breast cancer risk for lifetime
smoking exposure but not cigarettes per day among smokers.
British Journal of Cancer; https://doi.org/10.1038/s41416-021-01432-8
BACKGROUND
Breast cancer is the most common cancer in women, represent-
ing approximately one-quarter of all cancers diagnosed in
women worldwide.1 Besides well-established risk factors for
breast cancer, tobacco smoking has been widely studied as a
potential risk factor for breast cancer since it is also a leading
modifiable risk factor for cancers at sites not directly reached by
tobacco smoke.2,3 Carcinogens associated with tobacco smoke
include polycyclic aromatic hydrocarbons, aromatic amines
and N-nitrosamines.4 It is biologically plausible that tobacco
smoking may affect risk of breast cancer since metabolites of
lipophilic tobacco-associated carcinogens have been detected
in breast adipose tissue,5,6 and specific DNA adducts as well
as p53 gene mutations are found in the breast cancer tissue of
smokers.7–9
Based on the experimental and epidemiologic findings, evidence
is insufficient to establish a causal relationship between tobacco
smoking and breast cancer risk.2,10 Some of the inconsistencies in
findings could be attributed to a potential dual effect of smoking on
breast cancer.11 The anti-oestrogenic effect of smoking may
attenuate or mask the carcinogenic effects.12 In a recent pooled
analysis of 14 prospective cohort studies, adjusting for potential
confounding by alcohol intake as well as body mass index (BMI),
education, reproductive factors and other risk factors, a modest
association was found between smoking and breast cancer risk.13
There was also an increased risk with longer duration of smoking
prior to first birth, particularly for oestrogen receptor-positive
tumours. It is however difficult to establish causation based on
these observational studies.
Mendelian randomisation (MR) has been increasingly used to
strengthen causal inference in observational studies and under
certain assumptions is less vulnerable to residual confounding,
reverse causation and selection bias.14 MR uses genetic variants
such as single-nucleotide polymorphisms (SNPs) associated with
an exposure of interest as an instrumental variable (IV), which is
robust if three assumptions are met: (1) the genetic variants are
casually associated with the exposure, (2) the variants are not
associated with known or potential confounders for the
exposure–outcome relationships and (3) the variants are asso-
ciated with outcome only via the exposure of interest and not
through other pathways.15,16 Given the unclear causal nature of
the findings in observational studies, we conducted a MR analysis




We used data from 81 studies participating in the Breast Cancer
Association Consortium (BCAC), including 108,420 cases and
87,681 controls of European ancestry. Genotyping was performed
using two custom-made genotyping arrays: OncoArray in 68,242
invasive breast cancer cases and 52,367 controls (https://epi.
grants.cancer.gov/oncoarray/)17 and iCOGS arrays in 40,178 cases
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and 35,314 controls (http://ccge.medschl.cam.ac.uk/research/
consortia/icogs/).18 Genotype data were imputed based on the
1000 Genomes project Phase 3 as the reference panel using the
programme IMPUTE2.19 SNPs with high imputation quality
(imputation r2 > 0.5) were included. Overlapping participants
between datasets were excluded from the iCOGS dataset as the
OncoArray provides a better genomic coverage than the iCOGS
array. Demographic and epidemiologic data were harmonised
across BCAC sites based on a standardised protocol and derived
with respect to a reference date, which was date at diagnosis for
cases and date at interview for controls. For controls and cases
from the nested case-control studies, data from the baseline
interview were considered, or if available, follow-up information.
Chosen characteristics of the two datasets, including self-reported
smoking behaviours (e.g., smoking status, smoking heaviness and
smoking duration, including age at smoking initiation and lifetime
smoking exposure) are shown in Supplementary Table 1. Ethics
approval was obtained from the relevant institutional review
boards for all BCAC studies, and all participants provided written
informed consent.
Selection of SNPs associated with smoking exposure
Exposure variables were selected based on the availability of
associated genetic variants to reflect smoking exposure. We
included two quantitative smoking behaviour-related traits,
cigarettes per day (CPD; average number of cigarettes smoked
per day by ever-smokers) and lifetime smoking index (LSI;
composite score that captures lifetime smoking exposure by
taking into account smoking status as well as smoking duration,
heaviness and cessation in ever-smokers).20 The recent GWAS of
cigarettes per day from GSCAN consortium identified 55
conditionally independent genome-wide significant SNPs, explain-
ing 1.09% of the variance in a sample of 337,334 ever-smokers of
European ancestry.21 For LSI, 126 significantly associated SNPs,
0.36% explained variance in LSI, were identified based on a
sample of 426,690 individuals (never-smokers and ever-smokers)
of European ancestry from the UK biobank.20 The genetic scores of
the two smoking behaviour-related traits were reported to be
associated with significantly higher risks of lung cancer.20,22
For our analysis, SNPs were selected if they were reported to be
associated at genome-wide significance level (P ≤ 5 × 10−8) and
had a minor allele frequency (MAF) above or equal 1%. For each
behaviour phenotype, we filtered the list of behaviour-associated
SNPs so that the remaining SNPs were not in linkage disequili-
brium (LD) (r2 > 0.1). For CPD, the SNP with lowest P value
(rs10519203) of the correlated SNPs (rs12438181, rs28438420,
rs72740955, rs146009840, rs28681284, rs8040868, r2 > 0.01) was
retained. One SNP (rs4886550) was not available in our data and
without any proxy SNPs (LD, r2 > 0.8). Given that alcohol
consumption is a recognised confounder of the association
between smoking and breast cancer risk,23–25 we excluded nine
SNPs (three of CPD, six of LSI, respectively) correlated with any
alcohol consumption-associated SNPs (r2 > 0.1) from recent large-
scale GWAS (drinks per week, P ≤ 5 × 10−8).21 After exclusions, we
included a total of 164 variants associated with one of the
smoking traits; 44 and 120 variants, respectively, for CPD and LSI
(Supplementary Table 2). No variants overlapped between the two
smoking traits.
Statistical methods
Statistical power. Power calculations were conducted to esti-
mate the magnitude of effects detectable with our study size
assuming 5% α level and an R2 of 0.0109 for CPD and R2 of
0.0036 for LSI, which correspond to the variance in each
smoking behaviour explained by the SNPs used for this analysis.
Power calculations were performed using an online tool
available at http://cnsgenomics.com/shiny/mRnd/.26 Detailed
power calculations for all outcomes (invasive breast cancer,
ER-positive and ER-negative) to detect different odd ratios are
shown in Supplementary Table 3.
wPGS-based analyses. For our primary analysis, we generated
weighted polygenic scores (wPGSs) using individual-level data of
BCAC participants as follow: wPGS =
Pn
i¼1 βgx  αi , which is the
sum of the effect allele dosage (αi) (ranging from 0 to 2) for each
SNP weighted by the β-coefficient βgx for the effect of the genetic
variant (g) related to the smoking quality or/and duration (CPD,
and LSI) (x) (Supplementary Table 2).20,21 The wPGSs of LSI was
weakly correlated with wPGSs of CPD (0.17 in iCOGS and 0.03 in
OncoArray) in ever-smokers. Analysis of LSI was conducted using
all participants (including ever- and never-smokers), whereas that
of CPD was performed solely in ever-smokers, and based on
26,147 cases (7342 for iCOGS, 18,805 for OncoArray) and 26,072
controls (8489 for iCOGS, 17,583 for OncoArray). These inclusion
criteria correspond to those used in the GWAS studies that
identified the SNPs for the smoking traits.20,21
Association analysis of the wPGSs with breast cancer risk using
logistic regression was performed using fixed effect meta-analyses
combining iCOGS and OncoArray results based on heterogeneity
evaluated by Cochran’s Q statistics. The basic model (Model 1) was
adjusted for age (continuous), principal components (PCs) of
genetic ancestry (first ten PCs for iCOGS and OncoArray,
separately) and study site, as previously described.27 In order to
assess if the genetic instrument is independent of established risk
factors for breast cancer, associations of wPGSs with selected
breast cancer risk factors were assessed by linear regression for
continuous variables and logistic regression for categorical
variables (Supplementary Table 4). We adjusted for the risk factors
that were associated with wPGSs of at least one of the smoking
traits in Model 2. We additionally adjusted for alcohol assumption,
a well-known confounder of the association between breast
cancer risk and smoking, separately in Model 3 because of the
large amount of missing data. Participants with missing covari-
ables were excluded from all of the analyses.
Stratified analysis was performed to assess potential differences
in associations with breast cancer risk by menopausal status (pre-,
postmenopausal women) adjusting for age, study site and top ten
PCs. Heterogeneity was tested employing the likelihood ratio test
(LRT) for evaluating the multiplicative interaction terms in nested
models. Polytomous regression was used to estimate the
association according to oestrogen receptor (ER) status.
Scaling was applied to convert the wPGSs for CPD into
meaningful units through dividing them by linear regression
coefficients of self-reported CPD (0.35 per pack of cigarettes
per day). The regression coefficient of CPD was derived from a
meta-analysis of iCOGS and OncoArray data on smoking
behaviours among 26,072 among ever-smoker controls (8490
and 17,703 controls of iCOGS and OncoArray, respectively).
Two-sample MR analyses. Five different two-sample MR methods
using summary association data were applied: inverse-variance
weighted (IVW),28 MR Egger,29 weighted median,30 weighted
mode,31 and robust adjusted profile score (RAPS).32 Each of these
methods makes slightly different assumptions about the nature of
pleiotropy and therefore a roughly consistent point estimate
across the multiple methods provides the strongest evidence of
causal inference.28 The IVW method was implemented since the
instruments consisted of multiple SNPs.33 Multivariable MR
methods34 were conducted also using summary association data
from GWASs of alcohol consumption (drinks per week),21 body
mass index (BMI) among females35 and education attainment.36
To produce valid results, the IVW method requires that all
instruments are associated with the exposure of interest
(relevance assumption), but neither directly with the outcome of
interest (only via the exposure; exclusion restriction) nor any
confounders of the relationship between the exposure and the
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outcome (independence assumption).37 The intercept from MR-
Egger regression is a statistical test for horizontal pleiotropy,
whereas the slope can be interpreted as the smoking behaviour
effect on breast cancer adjusted for horizontal pleiotropy.29 This
method assumes however that the pleiotropic effects are
independent of the instrument strength (InSIDE assumption).
The weighted median estimator provides a valid causal estimate
when at least half of the instruments are valid.30 The estimate
from the weighted-mode analysis is valid when the largest group
of instruments with consistent MR estimates is valid.31 MR-RAPS
test extends the basic IVW random-effects approach by making
the weight each variant receives in the analysis a function of the
causal effect and the precision of the SNP-exposure association.32
The MR pleiotropy residual sum and outlier test (MR-PRESSO) was
also implemented to identify outlying genetic variants and
analyses were re-run after excluding these variants.38
All two-sample MR analyses using summary association data
were performed with respect to three cancer susceptibility
phenotypes: overall breast cancer (108,067 cases/88,386 controls)
as well as oestrogen receptor (ER)-positive (70,435 cases) and ER-
negative tumours (17,365 cases). Due to the nature of summary-
level data, the analyses of both LSI and CPD were conducted using
all samples regardless of smoking status.
R version 3.4.3 was used to conduct analyses. R package
“Mendelian randomisation”, “mr_raps” and “MR-PRESSO” were
used for two-sample MR analysis. All tests were considered at the
0.05 level of significance.
RESULTS
There was an association of wPGS for LSI with increased invasive
breast cancer risk (OR per SD 1.18, 95% CI: 1.07–1.30, P= 0.11 ×
10–2) whereas little evidence was found for an association
between wPGSs for CPD and invasive breast cancer (OR 1.02 per
pack of cigarettes per day, 95% CI: 0.78–1.19, P= 0.85) after
adjustment for age and study (Model 1) (Table 1). Several breast
cancer risk factors were associated with wPGSs of one of the
smoking traits (CPD or/and LSI), including ever breastfeeding,
menopausal status, age at menopause, BMI, age at first live birth,
parity and education level (Supplementary Table 4). Adjustment
for all of the identified risk factors did not change the association
substantially (Model 2) (wPGSs for LSI, OR per SD 1.24, 95% CI:
1.06–1.45, P = 0.60 × 10−2) (Table 1). The point estimate of
association between wPGS for LSI and invasive breast cancer risk
remained unchanged after additional adjustment for alcohol
consumption although imprecisely estimated (i.e. wide confidence
intervals) (Model 3) (OR per SD 1.13, 95% CI: 0.86–1.49, P= 0.39).
The association between wPGSs for CPD and invasive breast
cancer did not change after adjustments.
There was no evidence for effect heterogeneity of the
associations of LSI and CPD with breast cancer risk according to
ER status or menopausal status (Supplementary Fig. 1).
Using IVW random-effects analysis, positive associations of
genetically predicted LSI were found for overall breast cancer risk
(OR per SD 1.14, 95% CI: 1.02–1.28, P= 0.02) and breast cancers
according to ER status (OR per SD 1.14, 95% CI: 1.00–1.30, P= 0.04,
for ER-positive and OR per SD 1.14, 95% CI: 0.95–1.37, P= 0.17, for
ER-negative tumours) (Table 2, Supplementary Table 5 and
Supplementary Figs. 2–4). There was no indication of horizontal
pleiotropy based on the MR-Egger intercept test for any
outcomes. The point estimates of associations were consistent
across the different methods although the results based on MR-
Egger regression, and weighted mode method were imprecisely
estimated (i.e. wide confidence intervals). They remained sub-
stantially unchanged after multivariable adjustment for alcohol
consumption, BMI and education. The MR-PRESSO analysis
revealed three outliers for LSI. Removal of an outlier (rs2867112)
with respect to risk for overall breast cancer and ER-negative
cancer did not change the associations. No outlier was observed
with ER-positive tumour (Table 2, Supplementary Table 5 and
Supplementary Figs. 2–4).
For genetically predicted CPD, we found little evidence for an
association with overall breast cancer and ER subtypes using IVW
random-effects method (Table 2, Supplementary Table 5 and
Supplementary Figs. 2–4). There was no indication of horizontal
pleiotropy based on the MR-Egger intercept test. Results
across two-sample MR analyses were consistent in overall breast
cancer and ER subtypes without any indication of horizontal
pleiotropy from the MR-Egger intercept. The MR-PRESSO analysis
detected three outlying SNPs (rs11940255, rs1737894 and
rs73229090) although the outcome of IVW analysis after outlier
removed remained unchanged in overall breast cancer and ER-
positive tumour risk. No outlier was observed with ER-negative
disease (Table 2, Supplementary Table 5 and Supplementary
Figs. 2–4).
DISCUSSION
This MR study supports an association between genetically
predicted lifetime smoking exposure and increasing invasive
breast cancer risk but no clear association with cigarettes
per day among smokers. The estimates based on the wPGS for
the two smoking traits and several two-sample MR methods
were consistent.
Table 1. Associations of genetic risk scores for cigarette smoke exposure-related traits with breast cancer risk: results from Mendelian randomisation
analysis.
CPD LSI
No. of cases/controls ORd 95% CI P No. of cases/controls ORe 95% CI P
Model 1a 26,147/26,072 1.02 0.78–1.19 0.85 108,420/87,681 1.18 1.07–1.30 1.1 × 10−3
Model 2b 7360/7168 0.98 0.74–1.33 0.95 17,936/16,654 1.24 1.06–1.45 6.0 × 10−3
Model 3c 2892/2754 0.66 0.36–1.19 0.16 7716/7028 1.13 0.86–1.49 0.39
No. number, CPD cigarettes per day, LSI lifetime smoking index, OR odds ratio per year, CI confidence interval, P P value, BMI body mass index.
aAdjusted for age, sex and top ten PCs. P value for heterogeneity between iCOGS and OncoArray data of cigarettes per day and lifetime smoking index are
0.60, 0.09, respectively; bin addition to adjustment of Model 1, additionally adjusted for ever breastfeeding, postmenopausal status, age at menopause, BMI,
age at first live birth, parity and education level. P value for heterogeneity between iCOGS and OncoArray data of cigarettes per day and lifetime smoking
index are 0.96, 0.37, respectively; cin addition to adjustment of Model 2, additionally adjusted for alcohol assumption (glasses per day) P value for
heterogeneity between iCOGS and OncoArray data of cigarettes per day and lifetime smoking index are 0.80, 0.66 respectively; dOR per pack of cigarettes
per day; eOR per standard deviation.
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The LSI has not been assessed in studies of breast cancer risk
but the modest association found in this analysis is in line with the
modest associations of current and former smoking with invasive
breast cancer risk reported in the recent large pooled analysis.13
We did not find support for an association between cigarettes
per day in ever-smokers and invasive breast cancer risk, whereas
modest associations were reported for cigarettes per day in
current smokers compared with never-smokers in the pooled
analysis. With the restriction to ever-smokers, the MR analysis of
CPD had low statistical power for the very modest dose–response
association estimated by our data (Table 1) as well as that
reported in the pooled analysis.13
In addition to smoking exposure traits, we addressed two
dichotomous smoking status traits, namely smoking initiation and
smoking cessation, which account for the lifetime smoking
exposure. Despite a pooled analysis of epidemiological studies
reporting an increased risk of breast cancer associated with
current smokers compared to non-smokers (OR of 1.02),13 a recent
MR study found inconclusive evidence of association between
genetically predicted smoking initiation and breast cancer risk
using summary-level data (OR: 1.05, 95% CI: 0.99–1.12, P= 0.12 in
BCAC; OR: 0.97, 95% CI: 0.90–1.06, P= 0.51 in UK Biobank).39 We
conducted association analyses of wPGS of smoking initiation and
smoking cessation with breast cancer risk (see Supplementary
Note) and found no statically significant association for either
smoking initiation (OR 1.05, 95% CI 0.99–1.11, P= 0.08) or
smoking cessation (OR 1.06, 95% CI: 0.88–1.27, P= 0.52)
(Supplementary Table 6). The results remained unchanged after
adjusting for breast cancer risk factors (Supplementary Table 6).
We cannot rule out that the MR analysis of the smoking status
had low statistical power to detect the very modest association
estimated by our data (Table 1) along with that reported in the
pooled analysis.13 It is also possible that the MR analysis of
smoking status especially smoking initiation alone does not
capture the association between cigarette smoking and breast
cancer risk comparing to the LSI which accounts for other
smoking traits.
There are several not entirely resolved issues concerning the
association between smoking and breast cancer risks, such as
potential effect modification by timing of smoking exposure,
menopausal status and oestrogen receptor (ER) status, potential
confounding by alcohol consumption. We conducted an
association analysis between wPGS of age at smoking initiation
and invasive breast cancer (see Supplementary Note). The result
showed an inverse association but statistically nonsignificant
with low precision (OR 0.88, 95% CI: 0.25–3.07, P= 0.84)
(Supplementary Table 6). This is in line with the result of a
pooled analysis of epidemiological studies showing that women
who started smoking later than 24 years old were at lower
breast cancer risk than those who started smoking earlier when
compared to non-smokers.13 Smoking initiation in relation to
first birth has been considered an essential factor in the
association with breast cancer risk since the undifferentiated
breast epithelium is particularly susceptible to carcinogens
before the first birth.40 Indeed this appears to be supported by
findings of a stronger association with smoking with breast
cancer risk if initiated before first birth and a stronger influence
of smoking on breast cancer among women who started
smoking more than 10 years before the first full-term pregnancy
on breast cancer.13,41–46 Since the relevant information was only
available for a subset of study participants, we did not
have sufficient power to address potential differential associa-
tions according to timing of smoking exposure in relation to
first birth.
Stronger associations between smoking and breast cancer
among premenopausal women have been hypothesised since
the morphology of the breast and the endogenous hormone
levels change substantially during the menopausal transition,
and menopausal status alter other breast cancer risk factors.10
The MR results confirmed the lack of effect modification by
menopausal status also reported by previous epidemiological
studies.13,47,48 Despite early evidence against a differential
association by ER status,2,3 recent epidemiologic studies
reported a stronger association for risk of ER-positive breast
cancer.10,13,41 We did not find clear evidence for heterogeneity
by ER status although power to detect effect heterogeneity was
limited particularly due to the small sample size for ER-negative
disease.
Table 2. Association of cigarette smoke with overall breast cancer risk: results from the two-sample Mendelian randomisation using summary statistics.
CPD LSI
ORi 95% CI P ORi 95% CI P
IVW summary statisticsa 1.02 0.89–1.17 0.74 1.14 1.02–1.28 2.5 × 10−02
Multivariable IVW summary statisticsa,b 1.05 0.92–1.20 0.49 1.38 1.08–1.76 8.9 × 10−03
Estimate using IVW after outlier correcteda,c 1.01 0.88–1.16 0.87 1.17 1.05–1.31 6.2 × 10−03
MR-Egger regressiona,d 0.98 0.77–1.24 0.84 1.39 0.88–2.20 0.15
MR multivariable Egger regressiona,b,e 1.03 0.82–1.29 0.82 1.36 0.88–2.11 0.17
MR weighted median estimatora,f 1.06 0.93–1.20 0.40 1.17 1.02–1.33 2.1 × 10−02
MR robust adjusted profile score estimatora,g 1.02 0.94–1.12 0.57 1.44 1.32 0 1.58 4.7 × 10−15
MR weighted modea,h 1.01 0.89–1.15 0.84 1.23 0.86–1.75 0.26
OR odd ratio, MR Mendelian randomisation, IVW inverse-variance weighted, CI confidential interval, CPD cigarettes per day, LSI lifetime smoking index, RAPS
robust adjusted profile score.
All two-sample MR analyses using summary-level data were performed in all samples regardless of smoking status (108,067 overall breast cancer cases/88,386
controls); aestimate derived using summary statistics (28); bmultivariable analysis after adjusting for genetically predicted alcohol consumption (drinks per week),
body mass index and education attainment by using summary-level data from GWAS outcome (alcohol assumption (21), body mass index (BMI) among female
(35) and education attainment (36); cthe MR pleiotropy residual sum and outlier test (MR-PRESSO) was implemented to identify outlying genetic variants
(rs11940255, rs1737894 and rs73229090 for CPD; rs2867112 for LSI) and analyses were re-run after excluding these variants (38); dthe MR-Egger intercept yielded
no indication of strong pleiotropic effects (CPD: β0= 0.24E-04, P= 0.99; LSI: β0=−3.1E-03, P= 0.37);
ethe multivariable MR-Egger intercept yielded no indication
of strong pleiotropic effects (CPD: β0= 6.88E-04, P= 0.83; LSI: β0= 3.2E-04, P= 0.93);
festimates derived using weighted median estimator approach, where 50%
of the variants included in each genetic instrument are assumed to be invalid (30); gestimates derived using Mendelian randomisation robust adjusted profile
score (MR-RAPS) method (32); hestimates derived using weighted mode estimator approach, where the largest group of instruments with consistent MR
estimate are assumed to be valid (31); iOR per standard deviation.
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Previous epidemiologic studies have addressed the confound-
ing effect by alcohol consumption and found an association of
smoking with breast cancer risk after stratifying on alcohol
consumption.13,41–43 We addressed this issue by excluding SNPs
associated with alcohol intake from the wPGS. However, the
results did not change significantly in sensitivity analyses with
wPGS, including the overlapping alcohol consumption-associated
SNPs (Supplementary Table 7). Also, our multivariable analyses
adjusting for alcohol consumption yielded association estimates
that remained unchanged. The lower precision can be attributed
to the reduced dataset that required information on alcohol intake
with the ensuing diminished power.
Despite epidemiological evidence indicating alcohol con-
sumption as an established risk factor for breast cancer risk,49 a
recent MR study reported no significant association of breast
cancer risk with genetically predicted alcohol intake using
summary association data.39 We conducted an analysis between
wPGS of alcohol consumption and invasive breast cancer
using individual-level data (see Supplementary Note). We found
no clear evidence of association between genetically predicted
alcohol consumption and invasive breast cancer (OR: 0.98,
95% CI: 0.86–1.11, P= 0.74). The association remained
unchanged after adjusting for LSI (OR: 0.88, 95% CI: 0.72–1.09,
P= 0.25).
Strengths and limitations
Despite the relatively large sample size used for our analyses,
weak statistical power to detect modest associations should be
considered when interpreting the results. The power calculation
shows that our study had 68% power to detect an OR of 1.20 per
SD change in LSI but only around 9% power for an OR of 1.05 in
combined dataset (iCOGS and OncoArray) (Supplementary
Table 3). Since the reported order of magnitude for associations
with CPD is around 1.05 per ten cigarettes,13 we cannot exclude
that the lack of association observed in the MR analysis
particularly regarding CPD may be due to limited power. The
unit for LSI is not scaled due to the nature of the phenotype. The
reported order of magnitude for associations with LSI can
therefore not be directly compared with the relative risk
estimates for smoking from observational studies.
MR estimates have a causal interpretation only if the
assumptions of the instrumental variable approach hold. Even
though we performed extensive sensitivity analyses to detect
potential violations, it is difficult to prove the validity of the
assumptions. The LSI captures multiple aspects of smoking
behaviours, which could have introduced more potential for
horizontal pleiotropy. The more diffuse the definition of
smoking, the more lifestyle factors might be correlated, making
it especially important to test for horizontal pleiotropy. No
evidence of pleiotropic effects was found by conducting various
sensitivity analyses; however, residual pleiotropy is difficult to
exclude and should be considered.
The genetic instrument for LSI allows for the use of the large
entire sample to conduct MR analysis without stratifying on
smoking status. The analyses for CPD were restricted to smokers
by reason that the CPD-associated SNPs were identified among
ever-smokers in the GWAS study,21 which reduce statistical
power to detect an association. Moreover, we should note that
restricting to ever-smokers may induce a sampling bias and
invalidate the MR assumptions. By restricting to smokers,
smoking initiation can open up the path from exposure (wPGS
for CPD) to outcome (breast cancer risk). It can make the
association between smoking and breast cancer risk appear
weaker by removing a part of the association that is attributable
to smoking initiation.
Another limitation is that our analysis was restricted to
participants of European ancestry; therefore, our results may not
apply to populations of other ethnicities. However, it reduces the
potential bias caused by population stratification.
Conclusion
In conclusion, this Mendelian randomisation analysis using both
individual-level data and summary statistics supports a causal
association between lifetime smoking exposure and breast cancer
risk. Larger studies for MR analysis are warranted to address
additional aspects of smoking behaviour.
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